Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $181

Benzinga Newsdesk www.benzinga.com Positive 88.3%

Neg 0% Neu 0% Pos 88.3%

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $165 to $181.